why choose us

First received: November 18, 2022

Clinical Trial: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucov

Brief Summary: The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer.One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.

Read more